Omalizumab for previously treated chronic spontaneous urticaria - guidance (TA339)

National Institute for Health and Care Excellence - NICE
Publication date:
08 June 2015


Evidence-based recommendations on omalizumab (Xolair) for treating severe chronic spontaneous urticaria in people of 12 and over.

Guidance development process

How we develop NICE technology appraisal guidance

Is this guidance up to date?

We reviewed the evidence in July 2018. We found nothing new that affects the recommendations in this guidance.

Next review: This guidance will be reviewed if there is new evidence that is likely to affect the recommendations.